器官移植供者来源性感染防治的研究进展

魏绪霞; 易慧敏

doi:10.3969/j.issn.1674-7445.2020.01.019

器官移植供者来源性感染防治的研究进展

doi: 10.3969/j.issn.1674-7445.2020.01.019

魏绪霞,
易慧敏^,

510630 广州，中山大学附属第三医院外科重症监护室

基金项目:

广东省自然科学基金 2018A0303130305

详细信息

作者简介:
魏绪霞，女，1983年生，硕士，主治医师，研究方向为重症医学，Email：weixuxia06@163.com

通讯作者:
易慧敏，女，1975年生，博士，主任医师，研究方向为重症医学，Email：ylhmin@hotmail.com

中图分类号: R617, R619+.3
计量
- 文章访问数: 236
- HTML全文浏览量: 100
- PDF下载量: 39
- 被引次数: 0
出版历程
- 收稿日期: 2019-10-13
- 网络出版日期: 2021-01-19
- 刊出日期: 2020-01-15

Research progress on prevention and treatment of donor-derived infection in organ transplantation

Wei Xuxia,
Yi Huimin^,

Intensive Care Unit of Surgery, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China

More Information

Corresponding author: Yi Huimin, Email: ylhmin@hotmail.com

摘要

摘要: 器官移植是治疗终末期器官衰竭的首选有效治疗方法，供者来源性感染(DDI)与移植术后受者感染发生率和病死率显著相关。供者筛选技术的改进以及早期的防治可以提高移植的安全性。本文总结了DDI细菌感染、真菌感染、病毒感染以及寄生虫感染的病原体特征，并就其防治的研究进展进行了简述，以期为减少DDI提供参考。
- 器官移植 /
- 供者来源性感染 /
- 防治 /
- 细菌感染 /
- 真菌感染 /
- 病毒感染 /
- 寄生虫感染
Abstract: Organ transplantation is the primary effective treatment for end-stage organ failure. Donor-derived infection (DDI) is significantly associated with the incidence of infection and mortality of the recipients after organ transplantation. Improvement of donor screening technology and early prevention and treatment can improve the safety of transplantation. In this article, the pathogenic characteristics of DDI bacterial infection, fungal infection, viral infection and parasitic infection were summarized, and the research progress upon the prevention and treatment were briefly introduced, aiming to provide reference for reducing DDI.
- Organ transplantation /
- Donor-derived infection /
- Prevention and treatment /
- Bacterial infection /
- Fungal infection /
- Viral infection /
- Parasitic infection

HTML全文

参考文献(40)

[1]	ISON MG, GROSSI P, AST Infectious Diseases Community of Practice. Donor-derived infections in solid organ transplantation[J]. Am J Transplant, 2013, 13 (Suppl 4):22-30. DOI: 10.1111/ajt.12095.
[2]	MUÑOZ P, FERNÁNDEZ NS, FARIÑAS MC. Epidemiology and risk factors of infections after solid organ transplantation[J]. Enferm Infecc Microbiol Clin, 2012, 30 (Suppl 2):10-18. DOI: 10.1016/S0213-005X(12)70077-0.
[3]	FISCHER SA. Is this organ donor safe?: donor-derived infections in solid organ transplantation[J]. Surg Clin North Am, 2019, 99(1):117-128. DOI: 10.1016/j.suc.2018.09.009.
[4]	FISHMAN JA, GREENWALD MA, GROSSI PA. Transmission of infection with human allografts: essential considerations in donor screening[J]. Clin Infect Dis, 2012, 55(5):720-727. DOI: 10.1093/cid/cis519.
[5]	WOLFE CR, ISON MG, AST Infectious Diseases Community of Practice. Donor-derived infections: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice[J]. Clin Transplant, 2019, 33(9):e13547. DOI: 10.1111/ctr.13547.
[6]	SHARMA TS, MICHAELS MG, DANZIGER-ISAKOV L, et al. Clinical vignettes: donor-derived infections[J]. J Pediatric Infect Dis Soc, 2018, 7(Suppl 2):S67-S71. DOI: 10.1093/jpids/piy129.
[7]	CAMARGO JF. Donor-derived infections in solid organ transplant recipients: challenging the 30-day paradigm[J]. Transpl Infect Dis, 2017, 19(2). DOI: 10.1111/tid.12665.
[8]	MATHERS AJ, COX HL, BONATTI H, et al. Fatal cross infection by carbapenem-resistant Klebsiella in two liver transplant recipients[J]. Transpl Infect Dis, 2009, 11(3):257-265. DOI: 10.1111/j.1399-3062.2009.00374.x.
[9]	ESCOLÀ-VERGÉ L, LOS-ARCOS I, JOSÉ GONZÁLEZ-LÓPEZ J, et al. Successful liver transplantation despite donor-transmitted ESBL-producing Klebsiella pneumoniae infection: case report and review of the literature[J]. Transpl Infect Dis, 2017, 19(5). DOI: 10.1111/tid.12743.
[10]	GALVÃO LM, OLIVEIRA APR, IBANÊS AS, et al. Fatal case of donor-derived colistin-resistant carbapenemase-producing Klebsiella pneumoniae transmission in cardiac transplantation[J]. Braz J Infect Dis, 2018, 22(3):235-238. DOI: 10.1016/j.bjid.2018.04.005.
[11]	WAN Q, LIU H, YE S, et al. Confirmed transmission of bacterial or fungal infection to kidney transplant recipients from donated after cardiac death (DCD) donors in China: a single-center analysis[J]. Med Sci Monit, 2017, 23:3770-3779. doi: 10.12659/MSM.901884
[12]	AGUADO JM, SILVA JT, FERNÁNDEZ-RUIZ M, et al. Management of multidrug resistant gram-negative bacilli infections in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations[J]. Transplant Rev (Orlando), 2018, 32(1):36-57. DOI: 10.1016/j.trre.2017.07.001.
[13]	ABAD CLR, RAZONABLE RR. Donor derived mycobacterium tuberculosis infection after solid-organ transplantation: a comprehensive review[J]. Transpl Infect Dis, 2018, 20(5):e12971. DOI: 10.1111/tid.12971.
[14]	NELSON CA, MURUA C, JONES JM, et al. Francisella tularensis transmission by solid organ transplantation, 20171[J]. Emerg Infect Dis, 2019, 25(4):767-775. DOI: 10.3201/eid2504.181807.
[15]	NAM H, NILLES KM, LEVITSKY J, et al. Donor-derived viral infections in liver transplantation[J]. Transplantation, 2018, 102(11):1824-1836. DOI: 10.1097/TP.0000000000002326.
[16]	BIXLER D, ANNAMBHOLTA P, ABARA WE, et al. Hepatitis B and C virus infections transmitted through organ transplantation investigated by CDC, United States, 2014-2017[J]. Am J Transplant, 2019, 19(9):2570-2582. DOI: 10.1111/ajt.15352.
[17]	GUPTA G, ZHANG Y, CARROLL NV, et al. Cost-effectiveness of hepatitis C-positive donor kidney transplantation for hepatitis C-negative recipients with concomitant direct-acting antiviral therapy[J]. Am J Transplant, 2018, 18(10):2496-2505. DOI: 10.1111/ajt.15054.
[18]	BETHEA ED, SAMUR S, KANWAL F, et al. Cost effectiveness of transplanting HCV-infected livers into uninfected recipients with preemptive antiviral therapy[J]. Clin Gastroenterol Hepatol, 2019, 17(4):739-747. DOI: 10.1016/j.cgh.2018.08.042.
[19]	PORRETT PM, REESE PP, HOLZMAYER V, et al. Early emergence of anti-HCV antibody implicates donor origin in recipients of an HCV-infected organ[J]. Am J Transplant, 2019, 19(9):2525-2532. DOI: 10.1111/ajt.15415.
[20]	BOTHA J, CONRADIE F, ETHEREDGE H, et al. Living donor liver transplant from an HIV-positive mother to her HIV-negative child: opening up new therapeutic options[J]. AIDS, 2018, 32(16):F13-F19. DOI: 10.1097/QAD.0000000000002000.
[21]	MALINIS M, BOUCHER HW, AST Infectious Diseases Community of Practice. Screening of donor and candidate prior to solid organ transplantation-guidelines from the American Society of Transplantation Infectious Diseases Community of Practice[J]. Clin Transplant, 2019, 33(9):e13548. DOI: 10.1111/ctr.13548.
[22]	ANDREI G, VAN LOON E, LERUT E, et al. Persistent primary cytomegalovirus infection in a kidney transplant recipient: multi-drug resistant and compartmentalized infection leading to graft loss[J]. Antiviral Res, 2019, 168:203-209. DOI: 10.1016/j.antiviral.2019.06.004.
[23]	FU W, MEROLA J, MALINIS M, et al. Successful treatment of primary donor-derived human herpesvirus-8 infection and hepatic Kaposi Sarcoma in an adult liver transplant recipient[J]. Transpl Infect Dis, 2018, 20(5):e12966. DOI: 10.1111/tid.12966.
[24]	MATHUR G, YADAV K, FORD B, et al. High clinical suspicion of donor-derived disease leads to timely recognition and early intervention to treat solid organ transplant-transmitted lymphocytic choriomeningitis virus[J]. Transpl Infect Dis, 2017, 19(4). DOI: 10.1111/tid.12707.
[25]	ANESI JA, SILVEIRA FP, AST Infectious Diseases Community of Practice. Arenaviruses and West Nile virus in solid organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice[J]. Clin Transplant, 2019, 33(9):e13576. DOI: 10.1111/ctr.13576.
[26]	SHAJI MATHEW J, MENON VP, MENON VP, et al. Dengue virus transmission from live donor liver graft[J]. Am J Transplant, 2019, 19(6):1838-1846. DOI: 10.1111/ajt.15270.
[27]	DARRIGO LG JR, DE SANT'ANNA CARVALHO AM, MACHADO CM. Chikungunya, Dengue, and Zika in immunocompromised hosts[J]. Curr Infect Dis Rep, 2018, 20(4):5. DOI: 10.1007/s11908-018-0612-2.
[28]	ZHANG J, LIN J, TIAN Y, et al. Transmission of rabies through solid organ transplantation: a notable problem in China[J]. BMC Infect Dis, 2018, 18(1):273. DOI: 10.1186/s12879-018-3112-y.
[29]	HIRSCH HH, RANDHAWA PS, AST Infectious Diseases Community of Practice. BK polyomavirus in solid organ transplantation-guidelines from the American Society of Transplantation Infectious Diseases Community of Practice[J]. Clin Transplant, 2019, 33(9):e13528. DOI: 10.1111/ctr.13528.
[30]	GOMEZ CA, SINGH N. Donor-derived filamentous fungal infections in solid organ transplant recipients[J]. Curr Opin Infect Dis, 2013, 26(4):309-316. DOI: 10.1097/QCO.0b013e3283630e4d.
[31]	中华医学会器官移植学分会, 中华预防医学会医院感染控制学分会, 复旦大学华山医院抗生素研究所.中国实体器官移植供者来源感染防控专家共识(2018版)[J].中华器官移植杂志, 2018, 39(1):41-52. DOI: 10.3760/cma.j.issn.0254-1785.2018.01.008. Branch of Organ Transplantation of Chinese Medical Association, Healthcare-associated Infection Control of Chinese Preventive Medicine Association, Institute of Antibiotis in Huashan Hospital of Fudan University. The consensus on donor-derived infection control of solid organ transplantation in China(2018)[J]. Chin J Organ Transplant, 2018, 39(1):41-52. DOI: 10.3760/cma.j.issn.0254-1785.2018.01.008.
[32]	KONTOYIANNIS DP, MARR KA, PARK BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database[J]. Clin Infect Dis, 2010, 50(8):1091-1100. DOI: 10.1086/651263.
[33]	SUN HY, WAGENER MM, SINGH N. Cryptococcosis in solid-organ, hematopoietic stem cell, and tissue transplant recipients: evidence-based evolving trends[J]. Clin Infect Dis, 2009, 48(11):1566-1576. DOI: 10.1086/598936.
[34]	SINGH N, HUPRIKAR S, BURDETTE SD, et al. Donor-derived fungal infections in organ transplant recipients: guidelines of the American Society of Transplantation, Infectious Diseases Community of Practice[J]. Am J Transplant, 2012, 12(9):2414-2428. DOI: 10.1111/j.1600-6143.2012.04100.x.
[35]	BADDLEY JW, FORREST GN, AST Infectious Diseases Community of Practice. Cryptococcosis in solid organ transplantation-guidelines from the American Society of Transplantation Infectious Diseases Community of Practice[J]. Clin Transplant, 2019, 33(9):e13543. DOI: 10.1111/ctr.13543.
[36]	MARTÍN-DÁVILA P, NORMAN F, FORTÚN-ABETE J, et al. Donor-derived multiorgan transmission of mixed P. malariae and P. ovale infection: impact of globalization on post-transplant infections[J]. Transpl Infect Dis, 2018, 20(5):e12938. DOI: 10.1111/tid.12938.
[37]	LE M, RAVIN K, HASAN A, et al. Single donor-derived strongyloidiasis in three solid organ transplant recipients: case series and review of the literature[J]. Am J Transplant, 2014, 14(5):1199-1206. DOI: 10.1111/ajt.12670.
[38]	ABANYIE FA, VALICE E, DELLI CARPINI KW, et al. Organ donor screening practices for Strongyloides stercoralis infection among US Organ Procurement Organizations[J]. Transpl Infect Dis, 2018, 20(3):e12865. DOI: 10.1111/tid.12865.
[39]	DEROUIN F, PELLOUX H, ESCMID Study Group on Clinical Parasitology. Prevention of toxoplasmosis in transplant patients[J]. Clin Microbiol Infect, 2008, 14(12):1089-1101. DOI:10.1111/j.1469-0691.2008. 02091.x.
[40]	LEVI ME, KUMAR D, GREEN M, et al. Considerations for screening live kidney donors for endemic infections: a viewpoint on the UNOS policy[J]. Am J Transplant, 2014, 14(5):1003-1111. DOI: 10.1111/ajt.12666.